These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

880 related items for PubMed ID: 9267033

  • 1. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation.
    Davies SW, Turmaine M, Cozens BA, DiFiglia M, Sharp AH, Ross CA, Scherzinger E, Wanker EE, Mangiarini L, Bates GP.
    Cell; 1997 Aug 08; 90(3):537-48. PubMed ID: 9267033
    [Abstract] [Full Text] [Related]

  • 2. Neuronal distribution of intranuclear inclusions in Huntington's disease with adult onset.
    Gourfinkel-An I, Cancel G, Duyckaerts C, Faucheux B, Hauw JJ, Trottier Y, Brice A, Agid Y, Hirsch EC.
    Neuroreport; 1998 Jun 01; 9(8):1823-6. PubMed ID: 9665608
    [Abstract] [Full Text] [Related]

  • 3. Transgenic mice expressing mutated full-length HD cDNA: a paradigm for locomotor changes and selective neuronal loss in Huntington's disease.
    Reddy PH, Charles V, Williams M, Miller G, Whetsell WO, Tagle DA.
    Philos Trans R Soc Lond B Biol Sci; 1999 Jun 29; 354(1386):1035-45. PubMed ID: 10434303
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Are neuronal intranuclear inclusions the common neuropathology of triplet-repeat disorders with polyglutamine-repeat expansions?
    Davies SW, Beardsall K, Turmaine M, DiFiglia M, Aronin N, Bates GP.
    Lancet; 1998 Jan 10; 351(9096):131-3. PubMed ID: 9439509
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Progressive formation of inclusions in the striatum and hippocampus of mice transgenic for the human Huntington's disease mutation.
    Morton AJ, Lagan MA, Skepper JN, Dunnett SB.
    J Neurocytol; 2000 Sep 10; 29(9):679-702. PubMed ID: 11353291
    [Abstract] [Full Text] [Related]

  • 8. Transgenic models of Huntington's disease.
    Sathasivam K, Hobbs C, Mangiarini L, Mahal A, Turmaine M, Doherty P, Davies SW, Bates GP.
    Philos Trans R Soc Lond B Biol Sci; 1999 Jun 29; 354(1386):963-9. PubMed ID: 10434294
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington's disease.
    Turmaine M, Raza A, Mahal A, Mangiarini L, Bates GP, Davies SW.
    Proc Natl Acad Sci U S A; 2000 Jul 05; 97(14):8093-7. PubMed ID: 10869421
    [Abstract] [Full Text] [Related]

  • 11. Neurological abnormalities in a knock-in mouse model of Huntington's disease.
    Lin CH, Tallaksen-Greene S, Chien WM, Cearley JA, Jackson WS, Crouse AB, Ren S, Li XJ, Albin RL, Detloff PJ.
    Hum Mol Genet; 2001 Jan 15; 10(2):137-44. PubMed ID: 11152661
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin.
    Schilling G, Becher MW, Sharp AH, Jinnah HA, Duan K, Kotzuk JA, Slunt HH, Ratovitski T, Cooper JK, Jenkins NA, Copeland NG, Price DL, Ross CA, Borchelt DR.
    Hum Mol Genet; 1999 Mar 15; 8(3):397-407. PubMed ID: 9949199
    [Abstract] [Full Text] [Related]

  • 15. Riluzole prolongs survival time and alters nuclear inclusion formation in a transgenic mouse model of Huntington's disease.
    Schiefer J, Landwehrmeyer GB, Lüesse HG, Sprünken A, Puls C, Milkereit A, Milkereit E, Kosinski CM.
    Mov Disord; 2002 Jul 15; 17(4):748-57. PubMed ID: 12210870
    [Abstract] [Full Text] [Related]

  • 16. The early cellular pathology of Huntington's disease.
    Li XJ.
    Mol Neurobiol; 1999 Jul 15; 20(2-3):111-24. PubMed ID: 10966117
    [Abstract] [Full Text] [Related]

  • 17. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice.
    Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, Hetherington C, Lawton M, Trottier Y, Lehrach H, Davies SW, Bates GP.
    Cell; 1996 Nov 01; 87(3):493-506. PubMed ID: 8898202
    [Abstract] [Full Text] [Related]

  • 18. Early motor dysfunction and striosomal distribution of huntingtin microaggregates in Huntington's disease knock-in mice.
    Menalled LB, Sison JD, Wu Y, Olivieri M, Li XJ, Li H, Zeitlin S, Chesselet MF.
    J Neurosci; 2002 Sep 15; 22(18):8266-76. PubMed ID: 12223581
    [Abstract] [Full Text] [Related]

  • 19. The selective vulnerability of nerve cells in Huntington's disease.
    Sieradzan KA, Mann DM.
    Neuropathol Appl Neurobiol; 2001 Feb 15; 27(1):1-21. PubMed ID: 11298997
    [Abstract] [Full Text] [Related]

  • 20. Neocortical expression of mutant huntingtin is not required for alterations in striatal gene expression or motor dysfunction in a transgenic mouse.
    Brown TB, Bogush AI, Ehrlich ME.
    Hum Mol Genet; 2008 Oct 15; 17(20):3095-104. PubMed ID: 18632688
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 44.